IL6-174G > C genetic polymorphism influences antidepressant treatment outcome |
| |
| Authors: | Serafim Carvalho Marlene Santos Luís Lima Jorge Mota-Pereira Paulo Pimentel Dulce Maia |
| |
| Institution: | 1. Hospital de Magalh?es Lemos, Porto, Portugal;2. Instituto Superior de Ciências da Saúde, Norte, Portugal;3. Molecular Oncology &4. Viral Pathology, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, Porto, Portugal;5. Núcleo de Investiga??o e Informa??o em Farmácia-Centrode Investiga??o em Saúde e Ambiente (CISA), School of Allied Health Technologies, Polytechnic Institute of Porto, Porto, Portugal;6. Faculty of Medicine, University of Porto, Porto, Portugal;7. Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal;8. Clínica Médico-Psiquiátrica da Ordem, Porto, Portugal;9. Trás-os-Montes e Alto Douro Hospital Center, Vila Real, Portugal |
| |
| Abstract: | Background: Major depressive disorder is a condition associated with dysregulated cytokine levels; among these, IL6. Furthermore, genetic variations within cytokine genes have been proposed to predict antidepressant treatment outcome.Objectives: This study aims to evaluate the role of IL6-174G?>?C and IL6R D358A A?>?C functional polymorphisms in antidepressant treatment phenotypes, specifically remission, relapse, and treatment resistant depression (TRD).Methods: The referred polymorphisms were genotyped in 80 MDD patients followed at Hospital Magalhães Lemos, Portugal, within a period of 27 months.Results: It was found that patients carrying IL6-174 GC genotype present a protection towards the development of TRD (OR?=?0.242; 95% CI?=?0.068–0.869; p?=?.038), when compared with GG genotype. Additionally, carriers of IL6-174?CC genotype remit earlier than patients with IL6-174 GG/GC genotypes, with a median time to remission of 6 weeks for CC carriers and 15 weeks for GG or GC carriers (p?=?.030, Log-rank test). No association was found between IL6R D358A genetic polymorphism and any of the treatment phenotypes evaluated.Conclusions: The IL6-174G?>?C polymorphism influences antidepressant treatment outcome in this sub-set of MDD patients, providing a putative mechanistic link for the dysregulated IL-6 levels described in the literature in patients with TRD. |
| |
| Keywords: | IL6 genetic polymorphisms antidepressants treatment resistant depression |
|
|
